Literature DB >> 12399623

Differential expression of MCP-1 and its receptor CCR2 in glucose primed human mesangial cells.

Ulf Janssen1, Eveline Sowa, Petra Marchand, Jürgen Floege, Aled O Phillips, Heinfried H Radeke.   

Abstract

BACKGROUND: Glomerular mononuclear cell infiltration is associated with the development of a diffuse glomerulosclerosis in patients with diabetic nephropathy. Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the recruitment and accumulation of monocytes and lymphocytes within the glomerulus. In the present study, we examined whether the ambient glucose concentration alters the expression of MCP-1 and its receptor CCR2 in primary human mesangial cells (HMC).
METHODS: MCP-1 mRNA expression was assessed by Northern blot and CCR2 mRNA expression by RT-PCR analysis. MCP-1 protein production was determined by ELISA. Migration studies were performed to assess functional MCP-1 receptor expression.
RESULTS: Exposure of HMC to 30 mM D-glucose led to a 30% increase in MCP-1 mRNA expression as compared to 5 mM D-glucose and osmotic controls while there was no difference in MCP-1 protein production. Simultaneously, CCR2 mRNA expression was down-regulated in HMC exposed to 30 mM D-glucose. 5 mM D-glucose primed HMC showed a dose-dependent migration towards MCP-1 that was dose-dependently inhibited by pertussis toxin, the broad-spectrum chemokine antagonist vMIP-II as well as the CCR2 receptor antagonist (1-8del)MCP-1--demonstrating functional activity of MCP-1 receptor expression in primary HMC. In accordance with the downregulatory effects of 30 mM D-glucose on CCR2 mRNA expression no migratory response towards MCP-1 was observed under these conditions. The additional proinflammatory stimulus TNFalpha increased MCP-1 protein production in 30 as compared to 5 mM D-glucose primed HMC (2,194 +/- 568 vs. 1,422 +/- 379 pg MCP-1/10(4) cells x ml in 30 vs. 5 mM D-glucose primed HMC +24 h TNFalpha 500 U/ml, p = 0.002). However, this was not associated with an increased MCP-1 mRNA transcription. The 30 mM D-glucose induced downregulation of CCR2 mRNA expression was prevented in the presence of TNFalpha.
CONCLUSION: High ambient glucose does not affect mesangial MCP-1 release and decreases its CCR2 receptor expression. However, in the presence of an inflammatory stimulus these effects of high glucose are reversed and an autocrine pathway of MCP-1 develops in mesangial cells. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399623     DOI: 10.1159/000065448

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Interindividual and intraindividual variations in postprandial glycemia peak time complicate precise recommendations for self-monitoring of glucose in persons with type 1 diabetes mellitus.

Authors:  Mette Dencker Johansen; Irene Gjerløv; Jens Sandahl Christiansen; Ole K Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

2.  Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis.

Authors:  L M McIntosh; J L Barnes; V L Barnes; J R McDonald
Journal:  Clin Exp Immunol       Date:  2008-11-25       Impact factor: 4.330

3.  Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells.

Authors:  S Giunti; G H Tesch; S Pinach; D J Burt; M E Cooper; P Cavallo-Perin; G Camussi; G Gruden
Journal:  Diabetologia       Date:  2007-10-30       Impact factor: 10.122

4.  CCL2/CCR2 augments the production of transforming growth factor-beta1, type 1 collagen and CCL2 by human CD45-/collagen 1-positive cells under high glucose concentrations.

Authors:  Akinori Hara; Norihiko Sakai; Kengo Furuichi; Yoshio Sakai; Motohiro Takeya; Richard Bucala; Naofumi Mukaida; Yoh Takuwa; Kouji Matsushima; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2013-04-06       Impact factor: 2.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.